[ Contents | Search | Post | Reply | Next | Previous | Up ]
From: Ann Packman
Date: 07 Oct 2009
Time: 20:52:36 -0500
Remote Name: 143.238.65.78
Hullo Nan and Bob, Thank you for your informative paper. There are two statements in it to which I want to respond. The first relates to your discussion of evidence-based practice where you say, “no one is distilling and integrating and disseminating the relevant data” for SLPs. I draw readers’ attention to the open access website SpeechBite (www.speechbite.com) where many studies of speech and language pathology interventions are summarized and rated for quality. Second, I would like to correct the implication that the Lidcombe Program, along with SpeechEasy (a commercial device) and Pagaclone (a drug) is “ ‘owned’ to some or all extent" by a company or other organization. The Lidcombe Program is not owned by any person, research group, institution, company, or organization. All reports and research conducted by the developers of the program are published in the public domain and the treatment manual can be downloaded from the website of the Australian Stuttering Research Centre anonymously and without cost. This means that any SLP who chooses to use the program can do so free of charge and without obligation, although training is recommended. While the early research into the program was conducted by the developers and colleagues, a number of studies and reports by independent research groups have now been published. Ann